Nifedipine enhances the cardioprotective effect of an angiotensin-II receptor blocker in an experimental animal model of heart failure

Hypertens Res. 2005 May;28(5):431-8. doi: 10.1291/hypres.28.431.

Abstract

This study was designed to examine the hypothesis that a calcium channel blocker nifedipine (CCB) could enhance the cardioprotective effect of an angiotensin-ll receptor blocker candesartan (ARB) in the treatment for heart failure. Isoproterenol (ISP) was injected into male rats at 300 mg/kg to produce progressive heart failure. Three months later, the rats were divided into 4 groups and treated for 4 weeks with 1) vehicle (n = 20), 2) ARB at 0.2 mg/kg/day (n = 6), 3) CCB at 10 mg/kg/day (n = 6), or 4) both drugs (n = 8). Rats injected with saline served as controls (n = 13). ISP caused severe myocardial degeneration and decreased the capillary density (D(cap)) of the left ventricular (LV) myocardium (mean +/- SD: 2,197 +/- 627 vs. 2,847 +/- 298 N/mm2 for normal controls), while increasing plasma thiobarbituric acid-reactive substances (TBARS; 3.6 +/- 1.1 vs. 1.9 +/- 0.5 nmol/ml). Although ARB therapy preserved cardiac morphology, it had little effect on D(cap) or oxidative stress. On the other hand, CCB decreased plasma TBARS and 4-hydroxy-2-nonenal protein expression in LV myocardium. Furthermore, the combination of CCB and ARB increased D(cap) and preserved the ultrastructure of LV myocardium, so this combination may be a useful option for the treatment of heart failure.

MeSH terms

  • Angiotensin II Type 1 Receptor Blockers / pharmacology*
  • Animals
  • Benzimidazoles / pharmacology*
  • Biphenyl Compounds
  • Body Weight
  • Calcium Channel Blockers / pharmacology*
  • Capillaries
  • Cardiotonic Agents / pharmacology
  • Coronary Circulation
  • Disease Models, Animal
  • Drug Synergism
  • Heart Failure / drug therapy*
  • Heart Failure / metabolism
  • Heart Failure / pathology
  • Hypertension / complications
  • Hypertension / drug therapy
  • Male
  • Microscopy, Electron
  • Myocardium / pathology
  • Myocardium / ultrastructure
  • Nifedipine / pharmacology*
  • Organ Size
  • Oxidative Stress / drug effects
  • Rats
  • Rats, Sprague-Dawley
  • Tetrazoles / pharmacology*
  • Thiobarbituric Acid Reactive Substances / metabolism
  • Ventricular Pressure

Substances

  • Angiotensin II Type 1 Receptor Blockers
  • Benzimidazoles
  • Biphenyl Compounds
  • Calcium Channel Blockers
  • Cardiotonic Agents
  • Tetrazoles
  • Thiobarbituric Acid Reactive Substances
  • Nifedipine
  • candesartan